arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CORCEPT THERAPEUTICS INC

CORT
$110.77 ▲ +2.88 (+2.66%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
77 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Bullish
auto_awesome

Analytical Summary

CORCEPT THERAPEUTICS INC shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $11.7B
Dividend Yield
Revenue Growth 31.7%
Op. Margin 16.1%
ROIC 5.5%
FCF / Share $0.29
Trailing P/E 276.9x
Price / Book 16.5x
FCF Yield 0.3%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

77-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$256.15M
↑ +31.7%
Net Income Profit after all expenses
$-31.76M
— 0.0%
Operating Margin Operating profit as % of sales
16.1%
↑ +153.6% 45th
FCF / Share Free cash flow per share
$0.29
↓ -30.7%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
65
Returns
81
Cash Quality
78

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 27 years · 77 quarters